Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet

Core Viewpoint - ImmunityBio (IBRX) shares have increased by 41.1% in the past four weeks, closing at $5.01, with a mean price target of $14.25 suggesting a potential upside of 184.4% [1] Price Targets - The average price target consists of three estimates ranging from a low of $4.75 to a high of $30, with a standard deviation of $13.74, indicating variability among analysts [2] - The lowest estimate suggests a decline of 5.2%, while the highest indicates a potential upside of 498.8% [2] Analyst Sentiment - Analysts show strong agreement on IBRX's ability to report better earnings than previously predicted, which supports the potential for stock upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.9%, with one estimate moving higher and no negative revisions [10] Zacks Rank - IBRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [11] Earnings Estimate Revisions - There is a strong correlation between trends in earnings estimate revisions and near-term stock price movements, suggesting that the positive revisions could lead to stock price increases [9]